

August 2024 Apple Health Preferred Drug List Class: Antidiabetics

Overview

- ▶ Recap:
 - ▶ Annual Utilization 2021 to 2023
 - ▶ Top 25 Classes
- ▶ Antidiabetics Subclasses
- ▶ GLP-1 Agonists

Annual Utilization - Background




▶ Methodology

- ▶ Pharmacy Point-of-Sale Claims
- ▶ Date Range: 1/1/2021 to 12/31/2023
- ▶ Fee-for-Service and Managed Care Claims




▶ Definitions:

- ▶ Paid Amount = Total amount paid, excluding rebates
- ▶ Net Paid = Total amount paid, including rebates
- ▶ PMPM = per member per month


Annual Utilization – Paid Amount



Annual Utilization – Net Paid



Annual Utilization - Claims




Top 25 Classes by Net Paid - Background

- ▶ Apple Health Drug Class (e.g. ANTIDEPRESSANTS : TRICYCLIC AGENTS)
 - ▶ Class – The component before the “ : ”
 - ▶ Example: ANTIDEPRESSANTS
 - ▶ There 64 Classes as of 2023
 - ▶ Subclass: - The component after the “ : ”
 - ▶ Example: TRICYCLIC AGENTS
 - ▶ Some drug classes do not contain a subclass (e.g. Cytokine & CAM Antagonists)
 - ▶ There were 494 Apple Health Drug Classes as of 2023
- ▶ Top 25 classes were included based on total cost, inclusive of rebates.

Top 25 Classes by Net Paid – Highest Cost Drug Classes 2023

Apple Health Class	Net Paid	Net Paid PMPM
CYTOKINE AND CAM ANTAGONISTS	\$133,131,487	\$5.03
HIV	\$89,753,775	\$3.39
ANTIDIABETICS	\$70,713,233	\$2.67
ONCOLOGY AGENTS	\$62,525,679	\$2.36
ASTHMA AND COPD AGENTS	\$60,255,354	\$2.28
ANTIPSYCHOTICS / ANTIMANIC AGENTS	\$54,367,088	\$2.06
ADHD / ANTI-NARCOLEPSY	\$40,900,700	\$1.55
RESPIRATORY AGENTS	\$40,621,994	\$1.54
ENDOCRINE AND METABOLIC AGENTS	\$40,144,170	\$1.52
SUBSTANCE USE DISORDER	\$39,998,839	\$1.51
ANTICONVULSANTS	\$33,309,701	\$1.26
ATOPIC DERMATITIS AGENTS	\$25,525,051	\$0.97
ANTIVIRALS	\$21,372,504	\$0.81
NEUROMUSCULAR AGENTS	\$20,063,789	\$0.76
PULMONARY HYPERTENSION AGENTS	\$18,752,807	\$0.71
MULTIPLE SCLEROSIS AGENTS	\$16,369,219	\$0.62
ANTIHYPERTENSIVES	\$16,324,506	\$0.62
GASTROINTESTINAL AGENTS	\$15,730,948	\$0.59
ANTIDEPRESSANTS	\$14,493,204	\$0.55
ANALGESICS	\$13,748,650	\$0.52
ANTIBIOTICS	\$13,733,677	\$0.52
HEMATOLOGICAL AGENTS	\$12,287,608	\$0.46
DERMATOLOGICS	\$11,419,916	\$0.43
ALLERGY	\$10,928,882	\$0.41
CONTRACEPTIVES	\$10,461,889	\$0.40

Top 25 Classes by Net Paid – PMPM Increase 2021 to 2023




Antidiabetics Drug Classes Analyses


Antidiabetics – Highest Net Paid Subclasses 2023

Apple Health Subclass	Net Paid	Net Paid PMPM	% of Antidiabetes Class Spend
GLP1 AGONISTS	\$29,991,831.84	\$ 1.13	42.5%
SGLT2 INHIBITORS	\$14,415,363.03	\$ 0.54	20.4%
INSULIN - LONG ACTING	\$ 8,285,888.09	\$ 0.31	11.7%
INSULIN - RAPID ACTING	\$ 7,061,331.80	\$ 0.27	10.0%
DPP4 INHIBITORS	\$ 4,171,829.58	\$ 0.16	5.9%
INSULIN - INTERMEDIATE ACTING	\$ 1,983,605.31	\$ 0.07	2.8%
DIABETIC OTHER	\$ 1,761,554.30	\$ 0.07	2.5%
BIGUANIDES	\$ 1,409,196.70	\$ 0.05	2.0%
INSULIN - PRE-MIXED	\$ 507,602.70	\$ 0.02	0.7%
INSULIN - SHORT ACTING	\$ 441,762.66	\$ 0.02	0.6%
SULFONYLUREAS	\$ 426,116.70	\$ 0.02	0.6%
THIAZOLIDINEDIONES	\$ 179,439.18	\$ 0.01	0.3%


Antidiabetics – PMPM 2021 to 2023



Antidiabetics – PMPM Change 2021 to 2023



Antidiabetics – PMPM Percent Change 2021 to 2023




Antidiabetics – Net Paid Summary

- ▶ From 2021 to 2023, the SGLT2 Inhibitors and GLP-1 Agonists Apple Health Antidiabetics subclasses have seen the greatest increase in expenses since 2021
 - ▶ GLP-1 Agonists expenses have increased over 217%
 - ▶ SGLT -2 inhibitors expenses have increased 113%
- ▶ GLP-1 Agonists continues to be the most expensive Apple Health antidiabetics subclass since 2021
 - ▶ Compared to the expenses of the 2nd most expensive antidiabetics subclass, GLP-1 agonists are more than double


Antidiabetics – Highest Net Paid Subclasses: Utilization 2023

Apple Health Subclass	Clients	Claims	Net Paid/ Client
BIGUANIDES	62734	235867	\$ 22.46
INSULIN - LONG ACTING	24813	117579	\$ 333.93
GLP1 AGONISTS	23813	123077	\$1,259.47
SGLT2 INHIBITORS	23394	120024	\$ 616.20
INSULIN - RAPID ACTING	18002	101777	\$ 392.25
SULFONYLUREAS	12779	49065	\$ 33.35
DPP4 INHIBITORS	5684	28786	\$ 733.96
DIABETIC OTHER	4227	8158	\$ 416.74
THIAZOLIDINEDIONES	3093	11859	\$ 58.01
INSULIN - INTERMEDIATE ACTING	2116	8741	\$ 937.43
INSULIN - SHORT ACTING	1050	5061	\$ 420.73
INSULIN - PRE-MIXED	1048	5473	\$ 484.35


Antidiabetics – Utilization 2021 to 2023



Antidiabetics – Utilization Change 2021 to 2023



Antidiabetics – Utilization Percent Change 2021 to 2023



Antidiabetics – Utilization Summary


- ▶ From 2021 to 2023, utilization of the SGLT2 Inhibitors and GLP-1 Agonists subclasses have increased significantly
 - ▶ Utilization of GLP-1 Agonists increased 98%
 - Ranking: 6th most utilized subclass to 3rd
 - ▶ Utilization of SGLT2 Inhibitors increased 84%
 - Ranking: 5th most utilized subclass to 4th
- ▶ The utilization of all other Antidiabetics subclasses have remained relatively stable

GLP-1 Agonists Drug Subclasses Analyses


GLP-1 Agonists – Net Paid

Label Name	Net Paid	Net Paid PMPM	Net Paid/ Client
VICTOZA	\$16,612,388	\$ 0.63	\$ 903.88
OZEMPIC	\$ 5,076,484	\$ 0.19	\$ 1,302.66
TRULICITY	\$ 3,222,252	\$ 0.12	\$ 2,374.54
MOUNJARO	\$ 3,093,251	\$ 0.12	\$ 3,294.20
BYDUREON BCISE	\$ 1,204,804	\$ 0.05	\$ 1,436.00
RYBELSUS	\$ 618,154	\$ 0.02	\$ 1,266.71
BYETTA	\$ 164,497	\$ 0.01	\$ 363.13


GLP-1 Agonists – Net Paid 2021 to 2023



GLP-1 Agonists – Net Paid Change 2021 to 2023




GLP-1 Agonists – Net Paid Percent Change 2021 to 2023




GLP-1 Agonists – Net Paid Summary

- ▶ Since 2021, the amount of expenses attributed to GLP-1 agonists have more than tripled
- ▶ More than half of the GLP-1 Agonists subclass expenses is attributed to Victoza (55.38%)
 - ▶ Victoza is a preferred product on the Apple Health Preferred Drug List
- ▶ From 2021 to 2023:
 - ▶ The amount spent on Victoza increased \$11.35 million
 - ▶ Increase of 215%
 - ▶ The amount spent on Ozempic increased \$4.71 million
 - ▶ Increase of 1,302%


GLP-1 Agonists – Utilization 2021 to 2023



GLP-1 Agonists – Utilization Change 2021 to 2023




GLP-1 Agonists – Utilization Percent Change 2021 to 2023



GLP-1 Agonists – Utilization Summary

- ▶ Since 2021, there has been a significant increase in the prescribing of GLP-1 Agonists
- ▶ Victoza is currently a preferred product on the Apple Health Preferred Drug List
 - ▶ More than half of clients using a GLP-1 agonist utilize Victoza (77% in 2023)
 - ▶ Victoza had the greatest increase in utilization compared to other GLP-1 Agonists
- ▶ From 2021 to 2023, non-preferred products saw the greatest percent increase in utilization compared to Victoza (91%)
 - ▶ Ozempic increased 399%
 - ▶ Rybelsus increased 221%

GLP-1 Agonist Modeling



Prior Authorization Determination Rates

Drug	Total Requests	Approved Requests	Percent Approved	Denied Requests	Percent Denied
Bydureon BCISE	246	139	56.5%	107	43.5%
Bydureon Pen	2	0	0.0%	2	100.0%
Byetta	7	4	57.1%	3	42.9%
Mounjaro	967	435	45.0%	532	55.0%
Ozempic	8151	2694	33.1%	5457	66.9%
Rybelsus	854	279	32.7%	575	67.3%
Trulicity	1933	957	49.5%	976	50.5%
Victoza	427	69	16.2%	358	83.8%

GLP-1 Agonists Policy – Effective 2/1/2022

